

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 April 2022 (07.04.2022)



(10) International Publication Number
WO 2022/069509 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) A61P 11/06 (2006.01)
C07D 413/14 (2006.01) A61K 31/4709 (2006.01)
C07D 453/02 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/076730

(22) International Filing Date:

29 September 2021 (29.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20382861.1 30 September 2020 (30.09.2020) EP

(71) Applicant: **ORIGO BIOPHARMA, S.L.** [ES/ES]; Parque
Empresarial de Touro., Parcelas 26-27. Fonte Díaz., 15822
Touro, A Coruña (ES).

(72) Inventors: **BOSSER ARTAL, Ramón**; Vallseca, 7, 08024
Barcelona (ES). **PAMPÍN CASAL, Begoña**; Rúa For-
carei, 5, portal 2, 1ºB, Arca, 15821 O Pino, A Coruña
(ES). **CASTRO PALOMINO LARIA, Julio**; Tecnocam-
pus Mataró, 3, Avenida Ernest Lluch, 32, Planta 4, oficina
01, Barcelona, 08302 Mataró (ES).

(74) Agent: **ABG INTELLECTUAL PROPERTY LAW,**
S.L.; Avenida de Burgos, 16D, Edificio Euromor, 28036
Madrid (ES).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: 2-(3-PYRIDIN-2-YL-4-QUINOLIN-4-YL-PYRAZOL-1-YL)-ACETAMIDE DERIVATIVES AS INHIBITORS OF
TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5

(57) Abstract: The present invention relates to novel 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as potent
inhibitors of transforming growth factor- β receptor I, (also named activin receptor-like kinase 5) (TGF β RI)/ALK5. Other objectives of
the present invention are to provide a procedure for preparing these compounds; pharmaceutical compositions comprising an effective
amount of these compounds; the use of the compounds for manufacturing a medicament for the treatment of pathological conditions
or diseases that can improve by inhibition of transforming growth factor- β receptor I (TGF β RI)/ALK5, such as respiratory diseases
including idiopathic pulmonary fibrosis, asthma, COPD and lung cancer, and dermal and ocular fibrotic conditions.



WO 2022/069509 A1